The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Some obese Americans on Medicare and Medicaid could get access to expensive weight loss drugs under a five-year experiment ...

Government programs may soon change how they approach a growing public health challenge that affects millions of Americans each year.

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...

If a new experiment pans out, Medicaid and Medicare could begin covering the costly weight-loss drugs that price out many ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...